NO963589L - Beskrivelse av kreftilstander ved MAGE-genuttrykking - Google Patents
Beskrivelse av kreftilstander ved MAGE-genuttrykkingInfo
- Publication number
- NO963589L NO963589L NO963589A NO963589A NO963589L NO 963589 L NO963589 L NO 963589L NO 963589 A NO963589 A NO 963589A NO 963589 A NO963589 A NO 963589A NO 963589 L NO963589 L NO 963589L
- Authority
- NO
- Norway
- Prior art keywords
- description
- gene expression
- mage gene
- cancer states
- mage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/204,727 US5512437A (en) | 1994-03-01 | 1994-03-01 | Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3 |
| US08/209,172 US5763165A (en) | 1994-03-10 | 1994-03-10 | Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 |
| US08/299,849 US5612201A (en) | 1991-05-23 | 1994-09-01 | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
| US08/346,774 US5512444A (en) | 1994-03-01 | 1994-11-30 | Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4 |
| PCT/US1995/002203 WO1995023874A1 (en) | 1994-03-01 | 1995-02-23 | Determination of cancerous conditions by mage gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO963589D0 NO963589D0 (no) | 1996-08-28 |
| NO963589L true NO963589L (no) | 1996-10-31 |
Family
ID=27498545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO963589A NO963589L (no) | 1994-03-01 | 1996-08-28 | Beskrivelse av kreftilstander ved MAGE-genuttrykking |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0871765B1 (de) |
| JP (1) | JPH09509832A (de) |
| KR (1) | KR100316209B1 (de) |
| AT (1) | ATE209690T1 (de) |
| AU (1) | AU698310B2 (de) |
| CA (1) | CA2184482A1 (de) |
| DE (1) | DE69524264T2 (de) |
| FI (1) | FI963393L (de) |
| NO (1) | NO963589L (de) |
| NZ (1) | NZ282536A (de) |
| WO (1) | WO1995023874A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908778A (en) | 1996-10-03 | 1999-06-01 | Ludwig Institute For Cancer Research | Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof |
| US6221593B1 (en) * | 1996-10-03 | 2001-04-24 | Ludwig Institute For Cancer Research | Method for determining cancer by determining expression of MAGE-10 |
| EP0972084A2 (de) | 1997-04-11 | 2000-01-19 | Micromet Gesellschaft für Biomedizinische Forschung mbH | Primer und verfahren zur detektion von tumorzellmetastasen |
| US6027924A (en) * | 1997-04-25 | 2000-02-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof |
| JP2001516009A (ja) * | 1997-07-17 | 2001-09-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ガン関連核酸及びポリペプチド |
| BR9907691B1 (pt) | 1998-02-05 | 2011-05-31 | derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. | |
| US6686147B1 (en) | 1998-07-15 | 2004-02-03 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
| IL141444A0 (en) | 1998-08-31 | 2002-03-10 | Urogenesys Inc | Phelix: a testis specific protein expressed in cancer |
| US6733998B1 (en) * | 1998-12-07 | 2004-05-11 | Sloan-Kettering Institute For Cancer Research | Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto |
| US6475794B1 (en) * | 1999-10-08 | 2002-11-05 | The Johns Hopkins University | Converting diploidy to haploidy for genetic diagnosis |
| US7393657B2 (en) | 2001-04-12 | 2008-07-01 | Imperial College Innovations Limited | Diagnosis and treatment of cancer: I |
| GB0612342D0 (en) * | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
| GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
| WO2016094309A1 (en) | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
| US20210187023A1 (en) | 2017-06-27 | 2021-06-24 | The Trustees Of Princeton University | Compositions And Methods For Enhancing Immunotherapy |
| GB201713078D0 (en) | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| CN111836635A (zh) | 2018-01-26 | 2020-10-27 | 剑桥企业有限公司 | 肽交换蛋白 |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| US12329816B2 (en) | 2018-08-24 | 2025-06-17 | The Trustees Of Princeton University | Immunotherapy with metabolic enzyme expression |
| GB201820444D0 (en) | 2018-12-14 | 2019-01-30 | Adaptimmune Ltd | Marker for T cell expansion |
| BR112022000319A2 (pt) | 2019-07-11 | 2022-03-15 | Kahr Medical Ltd | Heterodímeros e métodos de uso dos mesmos |
| GB201911954D0 (en) | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Lentiviral transduction methods |
| US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
| US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| US20240317871A1 (en) | 2020-12-30 | 2024-09-26 | Immunomic Therapeutics, Inc. | Anti-HVEM Antibodies |
| GB202303250D0 (en) | 2023-03-06 | 2023-04-19 | King S College London | Method and compounds |
| WO2025155971A1 (en) | 2024-01-19 | 2025-07-24 | Immunomic Therapeutics, Inc | Anti-activin receptor 1c (alk-7) receptor antibodies |
| GB202501534D0 (en) | 2025-02-03 | 2025-03-19 | Cambridge Entpr Ltd | Targeted phagocytic degradation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
-
1995
- 1995-02-23 AT AT95912584T patent/ATE209690T1/de active
- 1995-02-23 DE DE69524264T patent/DE69524264T2/de not_active Expired - Lifetime
- 1995-02-23 CA CA002184482A patent/CA2184482A1/en not_active Abandoned
- 1995-02-23 AU AU19682/95A patent/AU698310B2/en not_active Ceased
- 1995-02-23 JP JP7522934A patent/JPH09509832A/ja not_active Ceased
- 1995-02-23 FI FI963393A patent/FI963393L/fi unknown
- 1995-02-23 WO PCT/US1995/002203 patent/WO1995023874A1/en not_active Ceased
- 1995-02-23 KR KR1019960704814A patent/KR100316209B1/ko not_active Expired - Fee Related
- 1995-02-23 EP EP95912584A patent/EP0871765B1/de not_active Expired - Lifetime
- 1995-02-23 NZ NZ282536A patent/NZ282536A/en unknown
-
1996
- 1996-08-28 NO NO963589A patent/NO963589L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0871765A1 (de) | 1998-10-21 |
| DE69524264D1 (de) | 2002-01-10 |
| FI963393A7 (fi) | 1996-08-30 |
| FI963393A0 (fi) | 1996-08-30 |
| AU1968295A (en) | 1995-09-18 |
| AU698310B2 (en) | 1998-10-29 |
| ATE209690T1 (de) | 2001-12-15 |
| EP0871765A4 (de) | 1999-08-11 |
| FI963393L (fi) | 1996-08-30 |
| KR970701790A (ko) | 1997-04-12 |
| NO963589D0 (no) | 1996-08-28 |
| JPH09509832A (ja) | 1997-10-07 |
| KR100316209B1 (ko) | 2002-06-26 |
| WO1995023874A1 (en) | 1995-09-08 |
| DE69524264T2 (de) | 2002-07-18 |
| EP0871765B1 (de) | 2001-11-28 |
| CA2184482A1 (en) | 1995-09-08 |
| NZ282536A (en) | 1998-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO963589D0 (no) | Beskrivelse av kreftilstander ved MAGE-genuttrykking | |
| PT690675E (pt) | Acido nucleico que codifica um percursor de antigenio de rejeicao de tumor | |
| IT8220616A0 (it) | Procedimento per la fabbricazione di contenitori per gas e fluidi mediante assemblaggio di parti prefabbricate. | |
| ES2138662T3 (es) | Produccion de fragmentos de anticuerpos. | |
| NO885350L (no) | Fremgangsmaate ved bestemmelse av ioner i fluider. | |
| MX9203607A (es) | Anticuerpo monoclonal que define un antigeno glicolipido asociado con carcinomas pulmonares en humanos, de celulas no pequeñas. | |
| IT8123284A0 (it) | Gas.procedimento per la produzione di | |
| NO951747D0 (no) | Fremgangsmåte ved fremstilling av xylitol | |
| NO870770L (no) | Fremgangsmte for fremstilling av monoklonale antistoffer. | |
| NO155768C (no) | Fremgangsmaate for fremstilling av mineralfibre ved sentrifugering. | |
| NO159497C (no) | Laas for fastgjoering av broennverktoey. | |
| NO970030L (no) | Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2 | |
| NO892068L (no) | Fremgangsmaate ved fremstilling av naftatiozepinoner. | |
| ES2131929T3 (es) | Procedimiento ultrasensible para la determinacion de la troponina i cardiaca. | |
| ATE219163T1 (de) | Nachbehandelter diamantbeschichteter körper | |
| NO884986L (no) | Fremgangsmaate ved kontinuerlig fermentering av medier inneholdende karbohydrat ved hjelp av bakterier. | |
| DE19681410D2 (de) | Wandplatte für die Herstellung von Wänden | |
| IL65597A (en) | Preparation of 1alpha,24,25-trihydroxy-and 24,25-dihydroxy-cholesterol and certain novel intermediates used therein | |
| IT8620655A0 (it) | Processo per la sintesi di mono odi idrossifluoroalcani. | |
| BR9812229A (pt) | Processo para a purificação de antitrombina iii | |
| FR2691377B1 (fr) | Four tournant pour réaction chimique. | |
| IT7921552V0 (it) | Profilato intermedio per rivestimenti di pareti o soffitti munito di flange per il suo innesto elestico. | |
| NO891898D0 (no) | Fremgangsmaate ved fremstilling av naftotiazepinoner. | |
| NO874405D0 (no) | Fremgangsmaate til bestemmelse av naervaer av diagnostisk relevante stoffer, spesielt antistoffer eller antigener etter elisa-metoden ved fotometrisk vurdering. | |
| ATE163181T1 (de) | Verfahren zur herstellung von 2- cyaniminothiazolidin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |